Challenge fuels change.
The Medable of today outpaces industry benchmarks and delivers game-changing results, fueled by a culture that thrives on progress and perseverance. As the industry shifts, we’re leading the way, not just as a product innovator, but as a partner invested in your success.
Delivery
100%
On-time go-live
Delivery
100%
On-time data transfers
Quality
90%
Patient eCOA adherence
Delivery
98%
Devices shipped on time
Help desk support
89%
First contact resolution
Business insights
2.6x
Enterprise study growth
Delivery
35x
faster than drag-and-drop builders
Global access
120+
locales
“So proud of our collaboration which is positively impacting this space of the industry.”
GSK
Better today, ready for tomorrow
Product Innovation
By launching Medable AI, eCOA+, and Studio, we’ve streamlined trial execution, cut timelines by 50%, and automated critical tasks, empowering customers to focus on delivering life-changing therapies.
Process Excellence
Our sharpened focus on operational excellence has transformed how we deliver. With 98% device success and 95% on-time launches, we’ve built a foundation of precision and reliability to hit critical trial milestones seamlessly.
Partnership Culture
Through deep collaboration and patient-centric initiatives, we continue to build a culture of trust, innovation, and impact, ensuring every stakeholder benefits from meaningful progress.
Expanding access to life changing treatments.
Expanding global access
Medable currently operates in 70+ countries, enabling digital and decentralized trials worldwide, including regions such as Japan, France, and underserved remote areas.
Regional expertise and regulation support
Medable became the first U.S.-based clinical trial platform provider to receive approval from France’s Commission Nationale de l’Informatique et des Libertés (CNIL) for its eConsent and eCOA solutions for a partner Sponsor company.
Expertise and patient input across diverse therapeutic areas
Medable currently enables digital trials across 26 therapeutic areas and works with our expansive Patient Caregiver Network, which includes 90+ patient advocates and caregivers across 12 countries, representing 67 diverse health conditions.
Experience the award-winning platform designed for sponsors, sites, and participants.
Driving progress for sites, patients, and the industry.
Together with our partners and customers, we look forward to shaping the future of clinical research one breakthrough at a time to continue enabling treatments to patients faster.
Medable’s 2024 was a year of exceeding key milestones and helping our customers reach new heights. Take a look at the difference Medable has made with our year-end impact report.
Related content
Case study: Medable beats forecasted FPI date while raising eCOA adherence in Japan
A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan.
Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable todevelop an initiative to enhance the region’s patient and site experience.
Challenge fuels change: Medable impact report
Medable’s 2024 was a year of exceeding key milestones and helping our customers reach new heights.
Take a look at the difference Medable has made with our year-end impact report.
Case Study: Medable beats forecasted FPI date by taking eCOA off the critical path
A top-10 global pharmaceutical company came to Medable looking to standardize and scale their weight management trials. The trial was driven by a master protocol with multiple sub-studies across 70+ research sites.
The partner was concerned about the participant and site experience, particularly participant enrollment and study startup timelines, as the trial required participants to enroll through the master protocol before enrolling into a sub-study.
Read ahead to see how Medable accomplished this, beat the forecasted FPI date, and more.